Journal
THROMBOSIS AND HAEMOSTASIS
Volume 117, Issue 7, Pages 1258-1264Publisher
GEORG THIEME VERLAG KG
DOI: 10.1160/TH16-10-0814
Keywords
Atherosclerosis; atherothrombosis; therapeutic strategies
Categories
Funding
- Deutsche Forschungsgemeinschaft [SFB1123-A1]
- German Centre for Cardiovascular Research [MHA VD 1.2]
- European Research Council (ERC) [AdG o692511]
- Leducq foundation Transatlantic Network of Excellence CVGene(Fx)
- Institute Carlos III Networks TERCEL
- Ciber-Cardiovascular and MINECO-Retos
- European Commission [FP7-INNOVATION I HEALTH-F2-2013-602114]
- Athero-B-Cell
- Swiss National Science Foundation [310030_152912/1]
- Alexander von Humboldt Foundation
Ask authors/readers for more resources
Even two centuries after they were first described, atherosclerosis and atherothrombosis remain among the leading causes of death worldwide. Over the last decades it has become clear that atherosclerosis is not only a lipid-driven disease but also a multifactorial process largely driven by inflammatory mediators, an insight that has instigated additional research and drug development focussing on anti-inflammatory therapies. In this review, we will provide a brief historical overview, followed by a more general synopsis of the range of currently available state-of-the-art therapies for atherosclerosis and atherothrombosis. Finally, we will highlight some of the promising therapeutic strategies that are currently under intense investigation. We believe that the next years will witness highly interesting developments and clinical trials investigating yet more novel therapies, and at the same time looking into potential combinations of all available therapies. This prospect closes in on the ultimate goal, which is to reduce the residual risk that still persists despite present therapeutic options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available